Clinical Effect of Dapagliflozin Tablets Combined with Sacubitril Valsartan Sodium Tablets in the Treatment of Heart Failure
Objective:To explore and analyze the clinical effect of Dapagliflozin Tablets combined with Sacubitril Valsartan Sodium Tablets in patients with heart failure.Method:A total of 70 patients with heart failure admitted to the Youyang County People's Hospital of Chongqing from March 2022 to March 2023 were selected to carry out the clinical practice study.The patients were divided into odd-even groups by odd-even number method,and the single number was included in the control group(treated with Sacubitril Valsartan Sodium Tablets),and the even-number group was included in the observation group(treated with Dapagliflozin Tablets and Sacubitril Valsartan Sodium Tablets),with 35 cases in each group.The cardiac function indexes[brain natriuretic peptide(BNP),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD),left ventricular ejection fraction(LVEF)],neuroendocrine hormones[noreadrenaline(NE),angiotensin Ⅱ(AngⅡ)]before and after treatment and the total effective rate of treatment were compared between the two groups.Result:Before treatment,there were no significant differences in cardiac function indexes and neuroendocrine hormone levels between the two groups(P>0.05).After treatment,BNP,LVEDD,LVESD,NE and AngⅡ in the observation group were lower than those in the control group,and LVEF was higher than that in the control group,the differences were statistically significant(P<0.05).The total effective rate of the observation group was 97.14%,higher than 82.86%of the control group,and the difference was statistically significant(P<0.05).Conclusion:Patients with heart failure were treated with Dagaglizin Tablets combined with Sacubitril Valsartan Sodium Tablets for good therapeutic effect.
万方数据
维普
